|
Title
|
|
|
|
Moving osimertinib to first-line : the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?
|
|
|
Author
|
|
|
|
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Journal of thoracic disease / Guangzhou hu xi ji bing yan jiu suo; Hu xi ji bing guo jia zhong dian shi yan shi. - Hong Kong, 2009, currens
|
|
|
Publication
|
|
|
|
Shatin
:
Ame publ co
,
2018
|
|
|
ISSN
|
|
|
|
2072-1439
|
|
|
DOI
|
|
|
|
10.21037/JTD.2018.03.92
|
|
|
Volume/pages
|
|
|
|
10
:s:[9]
(2018)
, p. S1076-S1080
|
|
|
ISI
|
|
|
|
000431688000029
|
|
|
Pubmed ID
|
|
|
|
29849216
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (open access)
|
|
|
|
|
|